“Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases”, J of Skin, vol. 8, no. 1, p. s344, Jan. 2024, doi: 10.25251/skin.8.supp.344.